St. Jude Medical (STJ) Risk from Dear Doctor Letter is Limited, Cowen Says

October 11, 2016 9:45 AM EDT
Get Alerts STJ Hot Sheet
Price: $79.54 +1.07%

Rating Summary:
    10 Buy, 22 Hold, 1 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 14 | Down: 19 | New: 11
Trade STJ Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with's Dividend Insider Elite. Sign-up for a FREE trial here.

Cowen analyst Joshua Jennings weighed in on St. Jude Medical (NYSE: STJ) after the company issued a voluntary medical device advisory relating to a low rate of premature battery depletion in the high voltage portfolio (ICDs and CRT-Ds).

"Although these Dear Doctor letters are never a positive, it is common in the Cardiac Rhythm Management industry," Jennings said. "We see the risk to STJ's franchise as limited. We still anticipate that the ABT/ STJ transaction will close by the end of the year."

The firm maintained a Outperform rating and price target of $85

For an analyst ratings summary and ratings history on St. Jude Medical click here. For more ratings news on St. Jude Medical click here.

Shares of St. Jude Medical closed at $81.28 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, FDA, Short Sales, Trader Talk

Related Entities

Cowen & Co

Add Your Comment